Ebola Virus: Promising Vaccine Candidates

Crossmark: check for updates

Authors

  • Reema Sameem School of Science, BMS, No. 591 Galle Rd, Colombo 6, Sri Lanka
  • Sajani Dias School of Science, BMS, No. 591 Galle Rd, Colombo 6, Sri Lanka

DOI:

https://doi.org/10.17140/VROJ-2-106

Keywords:

Ebola virus, ZEBOV, rVSV, ChAd3, Vaccine, rAd5, Immunization, Clinical trials

Abstract

Ebola Virus Disease is among the deadliest viral diseases. The field of Ebola vaccine development has progressed over the years with numerous candidates in advanced stages of clinical development. Currently, there is no licensed vaccine against Ebola virus. This review aimed to discuss the promising Ebola vaccine candidates focusing on vaccines against ebola viruses in particular against Zaire ebola virus (ZEBOV). Although DNA vaccines have been evaluated in Phase I clinical studies, it demonstrates low immunogenicity. Thus far, the most successful vaccine platforms are the recombinant viruses including, replicating vesicular stomatitis virus (rVSV) and chimpanzee adenovirus 3 (ChAd3). The successful trials attests that rVSV vaccines will be submitted for licensing in the near future.

References

Leligdowicz A, Fischer WA 2nd, Uyeki TM, et al. Ebola virus disease and critical illness. Crit Care. 2016; 20(1): 217. doi: 10.1186/s13054-016-1325-2

Wambani RJ, Ogola PE, Arika WM, Rachuonyo HO, Burugu MW. Ebola virus disease: A biological and epidemiological perspective of a virulent virus. J Infect Dis Diagn. 2016; 1: 103. Web site. http://ir-library.ku.ac.ke/handle/123456789/14250. Accessed May 24, 2017.

Nakayama E, Saijo M. Animal models for Ebola and Marburg virus infections. Front Microbiol. 2013; 4: 267. doi: 10.3389/ fmicb.2013.00267

Laupland KB, Valiquette L. Ebola virus disease. Can J Infect Dis Med Microbiol. 2014; 25(3): 128-129.

Chan M. Ebola virus disease in West Africa — No early end to the outbreak. N Engl J Med. 2014; 371(13): 1183-1185. Web site. http://www.nejm.org/doi/pdf/10.1056/nejmp1409859. Accessed May 24, 2017.

Urbanowicz RA, McClure CP, Sakuntabhai A, et al. Human adaptation of Ebola virus during the West African outbreak. Cell. 2016; 167(4): 1079-1087e5.

Uyeki TM, Mehta AK, Davey RT, Jr., et al. Clinical management of Ebola virus disease in the United States and Europe. N Engl J Med. 2016; 374(7): 636-646. doi: 10.1016/j. cell.2016.10.013

Team WER. After Ebola in West Africa — Unpredictable risks, preventable epidemics. N Engl J Med. 2016; 375(6): 587- 596. doi: 10.1056/NEJMsr1513109

Burghardt K, Verzijl C, Huang J, Ingram M, Song B, Hasne M-P. Testing modeling assumptions in the West Africa Ebola outbreak. Sci Rep. 2016; 6: 34598. doi: 10.1038/srep34598

Sullivan N, Yang ZY, Nabel GJ. Ebola virus pathogenesis: Implications for vaccines and therapies. J Virol. 2003; 77(18): 9733-9737. doi: 10.1128/JVI.77.18.9733-9737.2003

Lai KY, Ng WYG, Cheng FF. Human Ebola virus infection in West Africa: A review of available therapeutic agents that target different steps of the life cycle of Ebola virus. Infect Dis Poverty. 2014; 3(1): 43. doi: 10.1186/2049-9957-3-43

Trunschke M, Conrad D, Enterlein S, Olejnik J, Brauburger K, Muhlberger E. The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals. Virology. 2013; 441(2): 135-145. doi: 10.1016/j.virol.2013.03.013

Diehl WE, Lin AE, Grubaugh ND, et al. Ebola virus glycoprotein with increased infectivity dominated the 2013-2016 Epidemic. Cell. 2016; 167(4): 1088-1098.e6. doi: 10.1016/j. cell.2016.10.014

Wilson JA, Bray M, Bakken R, Hart MK. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology. 2001; 286(2): 384-390. doi: 10.1006/viro.2001.1012

Kondratowicz AS, Maury WJ. Ebola virus: A brief review of novel therapeutic targets. Future Microbiol. 2012; 7(1): 1-4. doi: 10.2217/fmb.11.110

Mehedi M, Falzarano D, Seebach J, et al. A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J Virol. 2011; 85(11): 5406-5414. doi: 10.1128/JVI.02190-10

Blaney JE, Wirblich C, Papaneri AB, et al. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol. 2011; 85(20): 10605-10616. doi: 10.1128/JVI.00558-11

Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis. 2002; 8(5): 503-507. doi: 10.3201/eid0805.010284

Halfmann P, Ebihara H, Marzi A, et al. Replication-deficient ebolavirus as a vaccine candidate. J Virol. 2009; 83(8): 3810- 3815. doi: 10.1128/JVI.00074-09

Robert-Guroff M. Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol. 2007; 18(6): 546-556. doi: 10.1016/j.copbio.2007.10.010

Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. Vaccines. 2014; 2(3): 624-641. doi: 10.3390/ vaccines2030624

Dudek T, Knipe DM. Replication-defective viruses as vaccines and vaccine vectors. Virology. 2006; 344(1): 230-239. doi: 10.1016/j.virol.2005.09.020

Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000; 408(6812): 605-609. doi: 10.1038/35046108

Mast TC, Kierstead L, Gupta SB, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine. 2010; 28(4): 950-957. doi: 10.1016/j. vaccine.2009.10.145

Wu S, Kroeker A, Wong G, et al. An adenovirus vaccine expressing Ebola virus variant makona glycoprotein is efficacious in guinea pigs and nonhuman primates. J Infect Dis. 2016; 214(suppl 3): S326-S332. doi: 10.1093/infdis/jiw250

Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014; 20(10): 1126-1129. doi: 10.1038/nm.3702

Quinn KM, Zak DE, Costa A, et al. Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling. J Clin Invest. 2015; 125(3): 1129-1146. doi: 10.1172/JCI78280

Wong G, Richardson JS, Pillet S, et al. Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med. 2012; 4(158): 158ra146. doi: 10.1126/scitranslmed.3004582

O’Brien LM, Stokes MG, Lonsdale SG, et al. Vaccination with recombinant adenoviruses expressing Ebola virus glycoprotein elicits protection in the interferon alpha/beta receptor knock-out mouse. Virology. 2014; 452-453: 324-333. doi: 10.1016/j. virol.2013.03.028

Hensley LE, Mulangu S, Asiedu C, et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog. 2010; 6(5): e1000904. doi: 10.1371/journal.ppat.1000904

Sridhar S. Clinical development of Ebola vaccines. Ther Adv Vaccines. 2015; 3(5-6): 125-138. doi: 10.1177/205101361 5611017

Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine. 2010; 29(2): 304-313. doi: 10.1016/j.vaccine.2010.10.037

Zhu FC, Hou LH, Li JX, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: Preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet. 2015; 385(9984): 2272-2279. doi: 10.1016/S0140- 6736(15)60553-0

Geisbert TW, Bailey M, Hensley L, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol. 2011; 85(9): 4222-4233. doi: 10.1128/JVI.02407-10

Colloca S, Folgori A, Ammendola V, et al. Generation and screening of a large collection of novel simian Adenovirus allows the identification of vaccine vectors inducing potent cellular immunity in humans: A range of novel simian adenoviral vectors, which are capable of priming high levels of T cell responses in man, has been defined. Sci Transl Med. 2012; 4(115): 115ra2- 115ra2. doi: 10.1126/scitranslmed.3002925

Kardani K, Bolhassani A, Shahbazi S. Prime-boost vaccine strategy against viral infections: Mechanisms and benefits. Vaccine. 2016; 34(4): 413-423. doi: 10.1016/j. vaccine.2015.11.062

Milligan ID, Gibani MM, Sewell R, et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored Ebola vaccines: A randomized clinical trial. JAMA. 2016; 315(15): 1610-1623. doi: 10.1001/ jama.2016.4218

Tapia MD, Sow SO, Lyke KE, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: A phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016; 16(1): 31-42. doi: 10.1016/S1473-3099(15)00362-X

De Santis O, Audran R, Pothin E, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: A randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 16(3): 311-320. doi: 10.1016/S1473-3099(15)00486-7

Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee adenovirus vector Ebola vaccine — Preliminary report. N Engl J Med. 2017; 376: 928-938. doi: 10.1056/NEJMoa1410863

Zhang Q, Seto D. Chimpanzee adenovirus vector ebola vaccine — Preliminary report. N Engl J Med. 2015; 373(8): 775- 776. doi: 10.1056/NEJMc1505499#SA1

Group TPIW. A Randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med. 2016; 375(15): 1448-1456. doi: 10.1056/NEJMoa1604330

Zhou Y, Sullivan NJ. Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine. Curr Opin Immunol. 2015; 35: 131-136. doi: 10.1016/j.coi.2015.06.006

Ewer K, Rampling T, Venkatraman N, et al. A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA. N Engl J Med. 2016; 374(17): 1635-1646. doi: 10.1056/ NEJMoa1411627

Geisbert TW, Geisbert JB, Leung A, et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of Ebola virus. J Virol. 2009; 83(14): 7296-7304. doi: 10.1128/JVI.00561-09

Geisbert TW, Feldmann H. Recombinant vesicular stomatitis virus–based vaccines against Ebola and marburg virus infections. J Infect Dis. 2011; 204(Suppl 3): S1075-S1081. doi: 10.1093/ infdis/jir349

Mire CE, Miller AD, Carville A, et al. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis. 2012; 6(3): e1567. doi: 10.1371/journal. pntd.0001567

Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005; 11(7): 786-790. doi: 10.1038/nm1258

Wong G, Audet J, Fernando L, et al. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine. 2014; 32(43): 5722-5729. doi: 10.1016/j. vaccine.2014.08.028

Lai L, Davey R, Beck A, et al. Emergency postexposure vaccination with vesicular stomatitis virus–vectored Ebola vaccine after needlestick. JAMA. 2015; 313(12): 1249-1255. doi: 10.1001/jama.2015.1995

Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med. 2016; 374(17): 1647-1660. doi: 10.1056/NEJMoa1502924

Skrip LA, Galvani AP. Next steps for Ebola vaccination: Deployment in non-epidemic, high-risk settings. PLoS Negl Trop Dis. 2016; 10(8): e0004802. doi: 10.1371/journal.pntd.0004802

Regules JA, Beigel JH, Paolino KM, et al. A recombinant vesicular stomatitis virus Ebola vaccine - Preliminary report. N Engl J Med. 2015; 376: 330-341. doi: 10.1056/NEJMoa1414216

Huttner A, Dayer JA, Yerly S, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: A randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2015; 15(10): 1156-1166. doi: 10.1016/ S1473-3099(15)00154-1

Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: Interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015; 386(9996): 857-866. doi: 10.1016/S0140-6736(15)61117-5

Li H, Ying T, Yu F, Lu L, Jiang S. Development of therapeutics for treatment of Ebola virus infection. Microbes Infect. 2015; 17(2): 109-117. doi: 10.1016/j.micinf.2014.11.012

Downloads

Published

2017-05-31

How to Cite

Reema Sameem, & Sajani Dias. (2017). Ebola Virus: Promising Vaccine Candidates. Vaccination Research, 2(1), 1–6. https://doi.org/10.17140/VROJ-2-106

Issue

Vol. 2 No. 1 (2017): Volume 2 Issue 1 2017

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Vaccination Research (VR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.